877-202-0205     support@chemchart.com     @chemchart
        
Sign In    Register
   Reset Filters

Anxiogenics

Categories

Drugs acting on the nervous system (15)
Psychoactive drugs (15)
Cyclic compounds (5)
Aromatic compounds (4)
Convulsants (4)
Neurotoxins (4)
Pharmaceuticals (4)
Benzodiazepines (3)
Caffeine (3)
Drugs acting on the cardiovascular system (3)
Imidazobenzodiazepines (3)
Ketones (3)
Vasoconstrictors (3)
Xanthines (3)
Adverse effects of psychoactive drugs (2)
Antipsychotics (2)
Beta-Carbolines (2)
Caffeinated drinks (2)
Consumer Ingredients (2)
Effects of psychoactive drugs (2)
Fluoroarenes (2)
Food Additives (2)
Mutagens (2)
Psychopharmacology (2)
Tardive dyskinesia (2)
Tea (2)
Analgesics (1)
Anorectics (1)
Antiobesity drugs (1)
Cannabinoids (1)
Cannabis (1)
Chalcogenides (1)
Designer drugs (1)
Drugs acting on the gastrointestinal system and metabolism (1)
Five-membered rings (1)
Nervous system drug (1)
Nootropics (1)
Opioid antagonists (1)
Opioid receptor ligands (1)
Opioids (1)
Piperidines (1)
Psychoanaleptics (1)
Pyrazolecarboxamides (1)
Pyrazoles (1)
Six-membered rings (1)
Sulfides (1)
Thioethers (1)

Suppliers

Sigma Aldrich (5)
Matrix Scientific (3)
AK Scientific (2)
Toronto Research Chemicals (2)
TCI Chemicals (2)
Amazon (1)
Oakwood Chemical (1)

Caffeine (58-08-2, 95789-13-2)  
Vivarin  ·  No Doz  ·  Caffedrine
Caffeine is a central nervous system (CNS) stimulant of the methylxanthine class. It is the world's most widely consumed psychoactive drug. Unlike many other psychoactive substances, it is legal and unregulated in nearly all parts of the world.
flumazenil (78755-81-4)  
Ro 15-1788  ·  Romazicon  ·  Anexate
Flumazenil (also known as flumazepil, code name Ro 15-1788) is a selective benzodiazepine receptor antagonist available by injection and intranasal. It has antagonistic and antidote properties to therapeutically used benzodiazepines, through competitive inhibition. It was first introduced in 1987 by Hoffmann-La Roche under the trade name Anexate, but only approved by the FDA on December 20, 1991.
TETRABENAZINE (58-46-8)  
Nitoman  ·  Orphan Brand of Tetrabenazine  ·  Tetrabenazine Orphan Brand
Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorders. It is marketed under the trade names Nitoman in Canada and Xenazine in New Zealand, some parts of Europe and in the United States as an orphan drug. On August 15, 2008, the U.S.
Rimonabant (168273-06-1, 158681-13-1)  
Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) was an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1 and was the first drug approved in that class.
DMCM (82499-00-1)  
DMCM (methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate) is a drug from the beta-carboline family. It acts as a negative allosteric modulator of GABAA receptors, meaning that it causes the opposite effects to the benzodiazepine class of drugs. As such, DMCM has anxiogenic and convulsant properties, and is used in scientific research to induce anxiety so that new anxiolytic medications can be tested, and to produce convulsions so that anticonvulsant medications can be tested.
DMPX (14114-46-6)  
DMPX (3,7-dimethyl-1-propargylxanthine) is a caffeine analog which displays affinity to A2 adenosine receptors, in contrast to the A1 subtype receptors. DMPX had 28× and 15× higher potency than caffeine in blocking peripheral and central NECA-responses. The locomotor stimulation caused by DMPX (ED50 10 μmol/kg) was similarly higher than caffeine.
ZK-93426 (89592-45-0)  
ZK-93426 (ethyl-5-isopropoxy-4-methyl-beta-carboline-3-carboxylate) is a drug from the beta-carboline family. It acts as a weak partial inverse agonist of benzodiazepine receptors, meaning that it causes the opposite effects to the benzodiazepine class of drugs and has anxiogenic properties, although unlike most benzodiazepine antagonists it is not a convulsant and actually has weak anticonvulsant effects. In human tests it produced alertness, restlessness and feelings of apprehension, and reversed the effect of the benzodiazepine lormetazepam.
Sarmazenil (78771-13-8)  
Sarmazenil (Ro15-3505) is a drug from the benzodiazepine family. It acts as a partial inverse agonist of benzodiazepine receptors, meaning that it causes the opposite effects to most benzodiazepine drugs, and instead acts as an anxiogenic and convulsant. It is used in veterinary medicine to reverse the effects of benzodiazepine sedative drugs in order to rapidly re-awaken anesthetized animals.
LY 293284 (141318-62-9)  
LY-293284 is a research chemical developed by the pharmaceutical company Eli Lilly and used for scientific studies. It acts as a potent and selective 5-HT1A receptor full agonist. It was derived through structural simplification of the ergoline based psychedelic LSD, but is far more selective for 5-HT1A with over 1000x selectivity over other serotonin receptor subtypes and other targets.